Study confirms "real world" value of HPV vaccine

New research has confirmed that the Human Papillomavirus (HPV) vaccination has reduced the frequency of abnormal Pap test results and precancers in women. Scientists at The University of Queensland and QIMR Berghofer Medical Research Institute used Queensland Health datasets to show that women who were fully vaccinated were far less likely to develop the high-risk abnormalities that can lead to cervical cancer. Study spokesperson, Professor David Whiteman, said the findings showed the value of the national HPV vaccination program, which began in 2007. "We always knew the vaccine was safe and effective in the narrow, controlled environment of clinical trials. This significant study proves its "real world" value on a broad scale," Professor Whiteman said. "Australia was one of the first countries to undertake mass HPV vaccination. This analysis of how well the vaccine has worked in the first four years of the program supports the decision to roll it out across the country.
account creation

TO READ THIS ARTICLE, CREATE YOUR ACCOUNT

And extend your reading, free of charge and with no commitment.

Register


Login

Your Benefits

  • Access to all content
  • Receive newsmails for news and jobs
  • Post ads

myScience